Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome

Virus Adaptation and Treatment

Volumn 2, Issue 1, 2010, Pages 47-57

  Martin Lerner, A ^a   Beqaj, Safedin ^b   Fitzgerald, James T ^c   Gill, Ken ^d   Gill, Carol ^d   Edington, James ^d  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d The Dr A Martin Lerner   (United States)

Author keywords

Cfs; Chronic fatigue syndrome; EIPS ; Energy index point score ; Treatment; Valacyclovir; Valganciclovir

Indexed keywords

ACICLOVIR; ANTISTREPTOLYSIN; ATENOLOL; ATOVAQUONE; AZITHROMYCIN; CEFTRIAXONE; CIMETIDINE; DIGOXIN; DOXYCYCLINE; FAMCICLOVIR; FLUDROCORTISONE ACETATE; PENCICLOVIR; PROBENECID; VALACICLOVIR; VALGANCICLOVIR; VIRUS ANTIBODY;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANAPLASMA PHAGOCYTOPHILUM; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; BABESIA MICROTI; BABESIOSIS; BORRELIA BURGDORFERI; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HERPES VIRUS; HERPES VIRUS INFECTION; HERXHEIMER REACTION; HOLTER MONITORING; HUMAN; HUMAN GRANULOCYTIC ANAPLASMOSIS; HUMAN HERPESVIRUS 6; LONG TERM CARE; LONG TERM EXPOSURE; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIXED INFECTION; MORNING DOSAGE; MYALGIA; ORTHOSTATIC HYPOTENSION; PATIENT MONITORING; SCORING SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; SYNCOPE; TACHYCARDIA; THORAX PAIN; TREATMENT DURATION; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 77955380663     PISSN: None     EISSN: 11791624     Source Type: Book Series    
DOI: None     Document Type: Article

References (40)

1. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: A working case definition. Ann Intern Med. 1988:108;387-389.
2. Fukuda K, Straus SE, Hickie I, Sharp MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121:953-959.
3. Jason LA, Richman JA, Rademaker AW, et al. A community-based study of chronic fatigue syndrome. Arch Intern Med. 1999;159:2129-2137.
4. Straus SE. Chronic fatigue syndrome. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of Internal Medicine. 16th ed. New York, NY: McGraw Hill Publishers 2004.
5. Soto NE, Straus SE. Chronic fatigue syndrome and herpesviruses: The fading evidence. Herpes. 2000;7(2):46-50.
6. Stulemeijer M, deJong LW, Fiselier TJ, Hoogveld SW, Bleijenberg G. Cognitive behavior therapy for adolescents with chronic fatigue syndrome: Randomized controlled trial. BMJ. 2005;330:14. Erratum in: BMJ 2005;330:820.
7. Wallman KE, Morton AR, Goodman C, Grove R. Randomized controlled trial of graded exercise in chronic fatigue syndrome. Med J Aust. 2004;180:444-448.
8. Lombardi VC, Ruscetti FW, Das Gupta J, et al. Detection of an infectious retrovirus XMRV in blood cells of patients with chronic fatigue syndrome. Science. 2009;326:585-589.
9. Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci U S A. 2009;10:16351-16356.
10. McClure M, Wessely S. Chronic fatigue syndrome and human retrovirus XMRV. BMJ. 2010:340;c1099.
11. Rowe PC, Bou-Holaigah I, Kan JS, Calkins H. Is neurally mediated hypotension an unrecognised cause of chronic fatigue syndrome? Lancet. 1995;45:623-624.
12. Lerner AM, Lawrie-Hoppen C, Dworkin HJ. Repetitively negative changing T-waves at 24-h electrocardiographic monitors in patients with the chronic fatigue syndrome. Left ventricular dysfunction in a cohort. Chest. 1993;104:1417-1420.
13. Peckerman A, LaManca JJ, Dahl KA, et al. Abnormal impedance cardiography predicts symptom severity in chronic fatigue syndrome. Am J Med Sci. 2003:326;55-60.
14. Dworkin HJ, Lawrie C, Bohdiewiez P, Lerner AM. Abnormal left ventricular myocardial dynamics in eleven patients with the chronic fatigue syndrome. Clin Nucl Med. 1994:19;657-677.
15. Lerner AM, Goldstein J, Chang CH, et al. Cardiac involvement in patients with the chronic fatigue syndrome as documented with Holter and biopsy data in Birmingham, Michigan. Inf Dis Clin Pract. 1997:6;327-333.
16. Lerner AM, Dworkin HJ, Sayyed T, et al. Prevalence of abnormal cardiac wall motion in the cardiomyopathy associated with incomplete multiplication of EBV and/or CMV in patients with chronic fatigue syndrome. In Vivo. 2004;18:417-424.
17. Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunological abnormalities in chronic fatigue syndrome. J Clin Microbiol. 1990:28;1403-1410.
18. Tiev KP, Demettre E, Ercolano P, Bastidel L, Lebleu B, Cabane J. RNase levels in peripheral blood mononuclear cells: 37-kilodalton/83- kilodalton isoform ratio is a potential test for chronic fatigue syndrome. Clin Diag Lab Immunol. 2005:12;1259-1260.
19. McDermott C, Richards SC, Thomas PW, Montgomery J, Lewith G. A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant BioBran MGN-3 in chronic fatigue syndrome. QJM. 2006:99;461-468.
20. Brooks J, Roberts N, Whitehouse G, Majeed T. Proton magnetic resonance spectroscopy and morphometry of the hippocampus in chronic fatigue syndrome. Br J Radiol. 2000:73;1206.
21. Kerr J R, Petty R, Burke B, et al. Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J Infect Dis. 2008:197;1171-1184.
22. Lerner AM, Zervos M, Dworkin HJ, Chang CH, O'Neill W. Hypothesis: A unified theory of the cause of the chronic fatigue syndrome. Infect Dis Clin Pract. 1997:6;239-243.
23. Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT. IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with chronic fatigue syndrome. In Vivo. 2004:18;101-106.
24. Lerner AM, Beqaj SH, Deeter RG, et al. IgM serum antibodies to human cytomegalovirus nonstructural gene products p52 and CM2 (UL44 and UL57) are uniquely present in a subset of patients with chronic fatigue syndrome. In Vivo. 2002:16;153-160.
25. Beqaj SH, Lerner AM, Fitzgerald JT. Immunoassay with cytomegalovirus early antigens from gene products p52 and CM2 (UL44 and UL57) detects active infection in patients with chronic fatigue syndrome. J Clin Pathol. 2008:61;623-626.
26. Streblow DN, Varnum SM, Smith RD, et al. A proteomics analysis of human cytomegalovirus particles. In: Reddehase MJ, editor. Cytomegalovirus, Molecular Biology and Immunology. Norfolk, UK: Caister Academic Press; 2006.
27. Lerner Am, Beqaj SH, Fitzgerald JT. Validation of the Energy Index Point Score to serially measure degree of disability in patients withchronic fatigue syndrome. In Vivo. 2008:22;799-802.
28. Lerner AM, Zervos M, Dworkin HJ, et al. New cardiomyopathy: Pilot study of intravenous ganciclovir in a subset of the chronic fatigue syndrome. Infect Dis Clin Pract. 1997;6:110-117.
29. Lerner AM, Beqaj SH, Deeter RG, et al. A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: Improvement in left ventricular function. Drugs of Today. 2002:38(8):549-561.
30. Lerner AM, Beqaj SH, Deeter RJ, Fitzgerald JT. Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: Thirty-six month follow-up. In Vivo. 2007:21;707-713.
31. Komaroff AL. Is human herpesvirus 6 a trigger for chronic fatigue syndrome? J Clin Virol. 2006:37;S39-S46.
32. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valacyclovir after escalating single- and multipledose administration to normal volunteers. Clin Pharmacol Ther. 1993:54;595-605.
33. Tyring SK. Advances in the treatment of herpesvirus infection: The role of famciclovir. Clin Ther. 1998;20:661-670.
34. Purifoy DJ, Beauchamp LM, de Miranda P, et al. Review of research leading to new anti-herpesvirus agents in clinical development: Valacyclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for Varicella Zoster virus. J Med Virol. 1993:Suppl 1;139-145.
35. Straus SE. Epstein-Barr virus and human herpesviruses 6 and 7. In: Galasso GT, Whitley RJ, Merigan TC, editors. Antiviral Agents and Human Viral Diseases. 4th ed. Wickford, RI: Lippincott-Raven Publishers; 1997.
36. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis and babesiosis: Clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006:43:1089-134. Erratum in: Clin Infect Dis. 2007;45:941.
37. Kaplan EL. Rheumatic fever. In: Kasper DL, Iauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, editors. Harrison's Principles of Internal Medicine. 16th ed. New York, NY: McGraw Hill Publishers; 2005.
38. Heng HH. The conflict between complex systems and reductionism. JAMA. 2008:300;1580-1581.
39. Cho HJ, Hotopf M, Wessely S. The placebo response in the treatment of chronic fatigue syndrome: A systemic review and meta-analysis. Adv Psychosom Med. 2005:67;301-13.
40. Landolfo S, Gariglio M, Gribaudo G, Lembo D. The human cytomegalovirus. Pharmacol Ther. 2003:98;269-297.